Description
Indication & Scope
Encofosbuvir Tablets is used in combination with Netanasvir Phosphate to treat adult patients with chronic hepatitis C virus genotypes 1, 2, 3 and 6 infection who are treatment-naive or interferon-experienced, with or without compensated liver cirrhosis.
- Mechanism: Nucleotide prodrug HCV NS5B RNA-dependent RNA polymerase inhibitor, which is integrated into replicated viral RNA to cause chain termination and block HCV genome replication.
- Drug class: Direct-acting antiviral drug, HCV NS5B polymerase inhibitor, oral antiviral prescription medicine.
- Clinical use: Core component of pan-genotypic all-oral curative direct antiviral regimen for chronic hepatitis C infection.
| Generic Name | Encofosbuvir Tablets |
| Brand Name | DongYingHe |
| Ingredient | Encofosbuvir Tablets |
| Dosage Form | Tablets |
| Package | 0.3g*7 tablets*4 blisters/box |
| Conditions Treated | Chronic hepatitis C virus genotypes 1, 2, 3 and 6 infection, accompanied or not accompanied by compensated liver cirrhosis |
| Taboos | Patients with hypersensitivity to encofosbuvir; patients with decompensated liver cirrhosis; monotherapy for HCV infection is prohibited |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Store at 25°C±5°C, protected from light and moisture |
| Manufacturer | DongYangGuangChangJiang Pharmaceutical Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20250010 |
| Approval Date | Mar 25, 2025 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: Fixed dose of 2 tablets taken once a day, combined with Netanasvir Phosphate capsules.
Time: Taken once a day with meals for 12 weeks for non-cirrhotic patients, and the course can be extended for cirrhotic patients.
Instructions for use: Oral administration with meals to improve bioavailability. It must not be used as a single drug for HCV treatment.
Interaction: P-gp and BCRP inducers will reduce the blood concentration of encofosbuvir. Combined use with rifampin and St. John’s Wort is forbidden.
Side effects: Fatigue, headache, nausea, insomnia, pruritus and mild asthenia.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is the clinical role of Encofosbuvir Tablets?
It is used in combination with Netanasvir for pan-genotypic chronic hepatitis C treatment.
What is Encofosbuvir Tablets' antiviral mechanism?
It acts as an NS5B polymerase nucleotide prodrug to terminate HCV RNA chain replication.
Why cannot Encofosbuvir Tablets be used alone?
Monotherapy leads to low cure rates and high viral resistance risk in HCV treatment.
What substances reduce Encofosbuvir Tablets' therapeutic effect?
P-gp and BCRP inducers including rifampin and St. John’s Wort significantly decrease drug concentration.
DongYingHe® | Encofosbuvir Tablets | HCV | DengYueRX
INN: Encofosbuvir Tablets
Indications: Hepatitis C virus infections of gene types 1, 2, 3, and 6
Dosage Form: Tablets
Strength: 0.3g/tablet
